Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro.

Int J Pharm

Institute of Pharmaceutical Technology, Department of Pharmacy, University of Basel, Klingelbergstr. 50, 4056, Basel, Switzerland.

Published: October 2001

The transport of unfractionated (UH) and low molecular weight Heparin (LMWH) in human skin was investigated in vitro using heat separated epidermal membrane and dermis and the effect of liposomal formulations with Phospholipon(R) 80 (PL80) and Sphingomyelin (SM) was assessed. The distribution of Heparin within skin tissue was studied by the tape stripping method. Heparin concentrations were measured with a biological assay. Transepidermal water loss was determined to characterize barrier properties of skin. No consistent permeation of Heparin through epidermal membrane was detected. Penetration into the epidermal membrane was for LMWH significantly greater than for UH. Accumulation of UH was largely restricted to the outermost layers of the stratum corneum while LMWH penetrated into deeper epidermal layers. UH penetration into epidermis was detected for the PL80 liposomal formulation only. The extent of LMWH penetration was independent of the formulation, LMWH, however, showed a trend to accumulate in deeper epidermal layers for the PL80 compared to the aqueous formulation. Thus, molecular weight and liposomal formulations influenced the penetration pattern of Heparin in the epidermis. It can not be concluded whether the concentration of LMWH achieved at the blood capillaries is sufficient to exert a pharmacological effect. UH permeated readily through dermis irrespectively of formulation and its accumulation in the dermis was significantly enhanced and its lag time of permeation increased in the presence of SM liposomes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0378-5173(01)00832-8DOI Listing

Publication Analysis

Top Keywords

liposomal formulations
12
epidermal membrane
12
human skin
8
molecular weight
8
deeper epidermal
8
epidermal layers
8
heparin
6
lmwh
6
epidermal
5
heparin penetration
4

Similar Publications

Recent advancements in genistein nanocarrier systems for effective cancer management.

Med Oncol

March 2025

Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, 281406, India.

Cancer continues to be a significant global health concern, consistently ranking as one of the leading causes of mortality across diverse populations and socio-economic contexts. Genistein, a soy-derived isoflavonoid, has gained significant attention for its diverse health benefits, particularly its potent anticancer activity. Emerging pre-clinical and clinical evidences highlights its ability to modulate key cellular processes, including apoptosis, autophagy, angiogenesis, metastasis, immune responses and cell cycle regulation.

View Article and Find Full Text PDF

Onychomycosis significantly impacts approximately 20% of the global population. The physical barriers of the nail structure make fungal infections a persistent therapeutic challenge. Traditional approaches, including topical and oral antifungal agents, have limitations such as toxicities, low nail permeability, adverse effects, and high recurrence rates.

View Article and Find Full Text PDF

Cancer is a leading cause of death and life-threatening disease globally. It is connected to persistent tissue damage and unregulated cellular proliferation. In females, breast cancer plays a crucial role in death rates.

View Article and Find Full Text PDF

Extracellular vesicles (EVs) are secreted by most cell types and play a central role in cell-cell communication. These naturally occurring nanoparticles have been particularly implicated in cancer, but EV heterogeneity and lengthy isolation methods with low yield make them difficult to study. To circumvent the challenges in EV research, we aimed to develop a unique synthetic model by engineering bioinspired liposomes to study EV properties and their impact on cellular uptake.

View Article and Find Full Text PDF

Formulation and development of ACUPA-targeting PEGylated nanoliposomes for treatment of prostate cancer.

Tissue Cell

March 2025

Center for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospitals, Saveetha University, Chennai, India; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

A promising strategy for improving the effectiveness, specificity and safety of cancer treatment is targeted medication delivery. Prostate-specific membrane antigen (PSMA) is an effective biomarker for tracking and treating prostate cancer. In this study, we developed a PSMA-targeted drug delivery system by modifying PEGylated liposomal doxorubicin (PLD) with 2-(3-((S)-5-amino-1-carboxypentyl) ureido) pentanedioic acid (ACUPA), a small-molecule PSMA inhibitor, to enhance tumor targeting and therapeutic outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!